Publisert 28.03.2016

EPO patent granted

Regenics is pleased to announce the granting of EPO (European Patent Office) patent on its core technology on March 28th 2016 

Regenics recieved noticeof  the granting of EPO (European Patent Office) patent on its core technology for salmon roe extract for wound healing and other skin application on March 23rd 2016. This broadens proprietary protection of the companys core technology to all European countries, including Norway. It also in some areas extends the range of protection of the previous US PO patent USPTO 996671-15 covering the use of salmon egg extracts for skin care and wound healing in humans. The patent allows 23 European country coverage for Regenics skin technology. Regenics is actively filing new patents and extension to existing coverage. 

More info on IP coverage

 

 

Regenics AS have developed clinical proof of efficacy and safety  in human 2 degree burn wounds for our products Collex® and Vernex®.

The procudts are beeing developed as class III devices. WoundClear® is developed as a BLA/EU CP biotech drug.